Lannett CO Inc (LCI) |
|
6.39 0.11 (1.75%)
|
11-29 21:40 |
|
Open: |
6.23 |
Pre. Close: |
6.28 |
|
High:
|
6.41 |
Low:
|
6.205 |
|
Volume:
|
116,380 |
Market Cap:
|
266M |
|
|
|
|
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.415 - 6.445 |
6.445 - 6.474 |
|
Low:
|
6.123 - 6.157 |
6.157 - 6.19 |
|
Close:
|
6.332 - 6.388 |
6.388 - 6.439 |
|
Technical analysis |
as of: 2020-11-29 9:24:18 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 7.75 One year: 8.39 |
| Support: |
Support1: 5.75 Support2: 4.78 |
| Resistance: |
Resistance1: 6.63 Resistance2: 7.18 |
| Pivot: |
6.26  |
| Moving Average: |
MA(5): 6.26 MA(20): 6.34 
MA(100): 6.12 MA(250): 7.34 |
| MACD: |
MACD(12,26): -0.05 Signal(9): -0.06 |
| Stochastic oscillator: |
%K(14,3): 56.85 %D(3): 44.09 |
| RSI: |
RSI(14): 50.54 |
| 52-week: |
High: 10.34 Low: 4.89 Change(%): -26.9 |
| Average Vol(K): |
3-Month: 31968 10-Days: 24700 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.LCI has closed below upper band by 33.9%. Bollinger Bands are 39% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 24 Nov 2020
Lannett Co Inc (LCI) Soars 3.9% on November 24 - Equities.com
Tue, 24 Nov 2020
Should Value Investors Consider Lannett Company (LCI) Now? - Zacks.com
Tue, 10 Nov 2020
What is the Forecast Price for Lannett Company, Inc. (LCI) Stock? - InvestorsObserver
Tue, 10 Nov 2020
$135.78 Million in Sales Expected for Lannett Company, Inc. (NYSE:LCI) This Quarter - MarketBeat
Sat, 07 Nov 2020
Lannett Company, Inc. (NYSE:LCI) Is a Buzzing Hot Stock - Stocks Register
Fri, 06 Nov 2020
Earnings Miss: Lannett Company, Inc. Missed EPS And Analysts Are Revising Their Forecasts - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
42 |
| Shares Float (M) |
32 |
|
% Held by Insiders
|
23.02 |
|
% Held by Institutions
|
88.71 |
|
Shares Short (K)
|
8,440 |
|
Shares Short P. Month (K)
|
9,380 |
Stock Financials |
|
EPS
|
-0.710 |
|
EPS Est This Year
|
2.600 |
|
EPS Est Next Year
|
2.750 |
|
Book Value (p.s.)
|
7.600 |
|
Profit Margin
|
-5.09 |
|
Operating Margin
|
8.70 |
|
Return on Assets (ttm)
|
2.6 |
|
Return on Equity (ttm)
|
-9.0 |
|
Qtrly Rev. Growth
|
-0.7 |
|
Gross Profit (p.s.)
|
4.738 |
|
Sales Per Share
|
13.089 |
|
EBITDA (p.s.)
|
2.528 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
100 |
|
Levered Free Cash Flow (M)
|
72 |
Stock Valuations |
|
PE Ratio
|
-9.00 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.84 |
|
Price to Sales
|
0.49 |
|
Price to Cash Flow
|
2.67 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
